The company's core technology is based on self-organizing cardiac organoids, called Cardioids, which allow for cost-efficient and large-scale in-vitro analysis of crucial clinical parameters associated with various cardiac diseases. The Cardioid-based screening platform has the potential to revolutionize cardiovascular drug discovery.